Therapeutic management of a new case of LCAT deficiency with a multifactorial long-term approach based on high doses of angiotensin II receptor blockers (ARBs)

2008 ◽  
Vol 69 (03) ◽  
pp. 213-218 ◽  
Author(s):  
P. Aranda ◽  
P. Valdivielso ◽  
L. Pisciotta ◽  
I. Garcia ◽  
C. García-Arias ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Angiotensin Ii Receptor Blockers ◽  
Therapeutic Management ◽  
Angiotensin Ii Receptor ◽  
Receptor Blockers ◽  
High Doses ◽  
Lcat Deficiency

Long-term use of angiotensin II receptor blockers and risk of cancer: A population-based cohort analysis

2013 ◽  
Vol 167 (5) ◽  
pp. 2162-2166 ◽  
Author(s):  
Kang-Ling Wang ◽  
Chia-Jen Liu ◽  
Tze-Fan Chao ◽  
Chi-Ming Huang ◽  
Cheng-Hsueh Wu ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Cohort Analysis ◽  
Population Based ◽  
Angiotensin Ii Receptor Blockers ◽  
Angiotensin Ii Receptor ◽  
Receptor Blockers ◽  
Risk Of Cancer

LONG-TERM EFFECTS OF ANGIOTENSIN II RECEPTOR BLOCKERS ON PROTEINURIA

2004 ◽  
Vol 22 (Suppl. 2) ◽  
pp. S123-S124
Author(s):  
K. Eto ◽  
U. Onaka ◽  
T. Tsuchihashi ◽  
T. Kajioka ◽  
M. Nakayama ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Angiotensin Ii Receptor Blockers ◽  
Angiotensin Ii Receptor ◽  
Long Term Effects ◽  
Receptor Blockers

scholarly journals Valsartan: come versatilità e tollerabilità possono contribuireal contenimento della spesa sanitaria

2011 ◽  
Vol 12 (1S) ◽  
pp. 9-17
Author(s):  
Francesco Vittorio Costa
Keyword(s):  
Blood Pressure ◽  
Angiotensin Ii ◽  
Cardiovascular Disorder ◽  
Angiotensin Ii Receptor Blockers ◽  
Efficacy And Safety ◽  
Angiotensin Ii Receptor ◽  
Renal Protection ◽  
Receptor Blockers ◽  
Blood Pressure Goals

The search for a more specific and complete blockade of the hypertensive effects of angiotensin and of better tolerability than ACE-inhibitors has led to the development of angiotensin II receptor blockers (ARBs). ARBs have been evaluated in several large studies in terms of efficacy and safety in reducing blood pressure, as well as for cardiovascular and renal protection. Among angiotensin II receptor blockers, valsartan and losartan have the greatest number of therapeutic indications. In light of the costs related to cardiovascular disorder valsartan represents a potential long-term health cost saving strategy. Furthermore valsartan shows one of the lowest costs for patient achieving blood pressure goals and the higher level of persistence in its class.

The Impact of Angiotensin-II Receptor Blockers on Cardiovascular Events in Hypertensive Patients – Evidence from Real-life Databases

2010 ◽  
Vol 6 (3) ◽  
pp. 33
Author(s):  
Robert J Petrella ◽  
Keyword(s):  
Angiotensin Ii ◽  
Antihypertensive Drugs ◽  
Real Life ◽  
Angiotensin Ii Receptor Blockers ◽  
Angiotensin Ii Receptor ◽  
Real World Setting ◽  
Actual Experience ◽  
Receptor Blockers ◽  
Randomised Controlled ◽  
The Impact

It is widely recognised that hypertension is a major risk factor for the development of future cardiovascular (CV) events, which in turn are a major cause of morbidity and mortality. Blood pressure (BP) control with antihypertensive drugs has been shown to reduce the risk of CV events. Angiotensin-II receptor blockers (ARBs) are one such class of antihypertensive drugs and randomised controlled trials (RCTs) have shown ARB-based therapies to have effective BP-lowering properties. However, data obtained under these tightly controlled settings do not necessarily reflect actual experience in clinical practice. Real-life databases may offer alternative information that reflects an uncontrolled real-world setting and complements and expands on the findings of clinical trials. Recent analyses of practice-based real-life databases have shown ARB-based therapies to be associated with better persistence and adherence rates and with superior BP control than non-ARB-based therapies. Analyses of real-life databases also suggest that ARB-based therapies may be associated with a lower risk of CV events than other antihypertensive-drug-based therapies.

Sign in / Sign up

Export Citation Format

Share Document